|
|
|
|
|
|
|
|
|
21.11.25 - 10:30
|
Hofseth BioCare ASA: PRIMARY INSIDER NOTIFICATION (GlobeNewswire EN)
|
|
|
Christoph Baldegger, primary insider and member of the Board of Directors in Hofseth BioCare ASA ("HBC"), has subscribed for 368,320 Offer shares in the Subsequent Offering and Mr. Baldegger will hold 3,616,296 shares in HBC after the share capital is registered, equal to approximately 0.92 % of the total outstanding A-shares with voting rights. ...
|
|
|
21.11.25 - 10:15
|
Hofseth BioCare ASA: RESULTS OF SUBSEQUENT OFFERING (GlobeNewswire EN)
|
|
|
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN....
|
|
|
|
|
|
|
21.11.25 - 10:03
|
Anaptys Announces $100 Million Stock Repurchase Plan (GlobeNewswire EN)
|
|
|
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized an amended Stock Repurchase Plan under which the Company may repurchase up to $100.0 million of the Company's outstanding common stock, par value $0.001 per share. This amendment is in addition to the $6.4 million that remained as of Nov. 20, 2025 under the current $75.0 million Stock Repurchase Plan of which Anaptys has repurchased a total of 3,443,188 shares of common stock (11.2% shares outstanding before the start of this repurchase plan).Excluding any additional potential purchases under this Stock Repurchase Plan, Anaptys anticipates ending 2025 with approximately $300 million in cash, cash equivalents and investments, including an anticipated accrual of a one-time $75 million commercial sales milestone in Q4 2025 due from GSK once Jemperli achieves $1 billion in wor...
|
|
|
|
|
21.11.25 - 09:54
|
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary (GlobeNewswire EN)
|
|
|
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a Verified Complaint in Delaware Chancery Court, requesting a court declaration that TESARO, Inc. (“Tesaro”) has materially breached the parties' Collaboration and Exclusive License Agreement (“Collaboration Agreement”) and that GSK (Tesaro's corporate parent) has tortiously interfered with the Collaboration Agreement. Anaptys has requested that the court declare that Anaptys is entitled to all rights and remedies under the Collaboration Agreement....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21.11.25 - 08:03
|
Okeanis Eco Tankers Corp. - New Shares Issued and Commencement of Trading (GlobeNewswire EN)
|
|
|
ATHENS, Greece, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Reference is made to the stock exchange release by Okeanis Eco Tankers Corp. (the “Company”, OSE ticker code: “OET”, NYSE ticker code: “ECO”) on 19 November 2025 regarding the successful offering of 3,239,436 new common shares (the “Offer Shares”) of the Company at a price of USD 35.50 per Offer Share, raising gross proceeds of approximately USD 115 million (the “Offering”)....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
